External medicine combination for treating skin allergic disease

A technology for external use of drugs and compositions, applied in allergic diseases, skin diseases, drug combinations, etc., can solve the problems of inevitable adverse drug reactions and unsatisfactory effects, and achieve a good synergistic effect.

Active Publication Date: 2009-04-29
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] It is particularly noteworthy that currently antihistamine drugs are mostly administered orally in clinical practice, an...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • External medicine combination for treating skin allergic disease
  • External medicine combination for treating skin allergic disease
  • External medicine combination for treating skin allergic disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Allogeneic Passive Skin Allergy Test in Rats

[0018] 1. Experimental method:

[0019] 1. Group settings

[0020] Set up (1) model group, (8) positive drug (piyanping) control group, (2) boric acid liniment group (containing boric acid 3%), (3) zinc sulfate liniment group (containing zinc sulfate 5%), (4) Fexofenadine hydrochloride compound group 1 (fexofenadine hydrochloride + boric acid, containing fexofenadine hydrochloride 20mg / ml, boric acid 3%), (5) Fexofenadine hydrochloride compound group 2 (fexofenadine hydrochloride+zinc sulfate, containing fexofenadine hydrochloride 20mg / ml, zinc sulfate 5%), (6) fexofenadine hydrochloride compound 3 groups (fexofenadine hydrochloride+boric acid+ Zinc sulfate, containing fexofenadine hydrochloride 20mg / ml, boric acid 3%, zinc sulfate 5%), (7) fexofenadine hydrochloride liniment group (containing fexofenadine hydrochloride 20mg / ml), a total of 8 groups.

[0021] 2. Operation steps

[0022] Preparation of antiser...

Embodiment 2

[0033] Example 2 Mouse ear xenogeneic passive cutaneous anaphylaxis (PCA)

[0034] Mouse ear xenogeneic passive cutaneous anaphylaxis is a highly sensitive and reproducible model of type I allergy. The serum of sensitized rats (containing rich IgE antibodies) is intradermally injected into the auricles of normal mice to make them passively sensitized. When the antigen is attacked, the local vascular permeability of the auricle increases, and Evanslan is injected into the auricle. According to the amount of Evans blue infiltrated, it can reflect the degree of skin allergic reaction and the efficacy of antihistamine drugs.

[0035] 1. Experimental method:

[0036] Antiserum preparation: same as Example 1

[0037] 1. Group settings:

[0038] Set up respectively (1) model group, (2) positive drug (piyanping) control group, (3) benzoic acid group (containing benzoic acid 2%), (4) zinc sulfate group (containing zinc sulfate 8%), (5 ) loratadine compound recipe 1 group (loratadine...

Embodiment 3

[0049] Example 3 Effect of Chlorpheniramine Compound on Delayed Type Hypersensitivity (DTH) in Mice Induced by Dinitrofluorobenzene (DNFB)

[0050] Delayed type hypersensitivity (DTH) is a reaction dependent on T cells, and its main feature is that the sensitized body has a delayed inflammatory response at the site of antigen attack, and T cells in the DTH reaction are involved in graft rejection and graft versus host disease Therefore, it is necessary to study the influence of drugs on the induction and regulation of DTH response to find new drugs and clarify the mechanism of action.

[0051] DNFB is a hapten. After its dilution is applied to the skin of the abdomen, it combines with skin proteins to form a complete antigen, thereby stimulating T lymphocytes to proliferate into sensitized lymphocytes. After 4-7 days, apply it to the skin of ears or paws to cause local delayed-type allergic reactions, which generally reach the peak at 24-48 hours after antigen attack, so the s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Anaphylactic diseases comprising urticaria, papilla, subacute dermatitis, eczema, and the like, are skin diseases which seriously puzzle the human beings. In the invention, antihistamine, zinc salt and weak acid are prepared into a topical compound preparation, which not only reduces the untoward effect of drugs, avoids the first pass effect of the liver when feeding the drugs by mouth, avoids the blood concentration peak valley phenomenon caused by oral feeding, but also can improve the curative effect and is convenient for clinic application. Simultaneously pharmacological tests show that the topical compound preparation obtains excellent drug synergism to the anaphylactic skin diseases and has excellent effects on curing the anaphylactic diseases.

Description

technical field [0001] The invention belongs to the new technology of compound prescription for external use of medicine. Background technique [0002] Histamine is formed by the decarboxylation of histidine and is an autologous active substance widely present in the human body. Histamine has a strong effect. It can stimulate H1 and H2 receptors to cause vasodilation, increase capillary permeability, and drop blood pressure to cause shock. The fiber H1 receptor releases mediators such as catecholamines, stimulates the postganglionic fiber H2 receptor to produce rapid inflammatory effects, thus causing allergic skin diseases. [0003] Histamine is the main mediator of allergic skin diseases, and its pathogenesis mainly includes allergic reaction and non-allergic reaction. [0004] Allergy is also known as anaphylaxis. Modern medicine refers to this reaction as antigen-antibody reaction. It is generally said that allergic diseases refer to tissue or physiological dysfunction...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K33/22A61K33/30A61K31/4402A61K31/445A61K31/495A61K31/4545A61K31/54A61K31/60A61K31/704A61P17/00A61P37/08A61K31/138A61K31/19A61K31/192A61K31/194
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap